Surging demand for weight loss drugs runs into insurance claims denials

Insurers are increasingly denying coverage for a new generation of U.S. Food and Drug Administration-approved diabetes drugs that can also help patients lose weight, Axios reports. Insurers have resisted paying for weight-loss drugs like Wegovy, which costs $1,300 a month, on the that presumption is obesity is a behavioral affliction, despite evidence it can be linked to hormonal factors and insulin resistance.